Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1552 Trials   75151 News 


«12345678910111213...858859»
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion date, Trial primary completion date:  Combined Immunotherapies in Metastatic ER+ Breast Cancer (clinicaltrials.gov) -  Jan 28, 2025   
    P2,  N=102, Recruiting, 
    Trial completion date: Oct 2025 --> Oct 2028 | Trial primary completion date: Oct 2024 --> Oct 2027
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Enrollment open:  EVOLVE Study: The Real-life Clinical Practice With Tezepelumab in Greece (clinicaltrials.gov) -  Jan 28, 2025   
    P=N/A,  N=150, Recruiting, 
    Trial completion date: Oct 2025 --> Oct 2028 | Trial primary completion date: Oct 2024 --> Oct 2027 Not yet recruiting --> Recruiting
  • ||||||||||  SB202190 / Amgen, SP600125 / BMS
    Preclinical, Journal:  CXCL10 Enhances Acid-Sensing Ion Channel Currents in Rat Dorsal Root. (Pubmed Central) -  Jan 27, 2025   
    These results indicated that CXCL10/CXCR3 signaling enhanced ASIC-mediated electrophysiological activity in DRG neurons and nociception in rats via a p38 MAPK-dependent pathway, revealing a novel mechanism underlying pain. CXCL10/CXCR3 signaling may be an effective target in the treatment of pain associated with tissue acidification.
  • ||||||||||  Nplate (romiplostim) / Amgen, Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
    Retrospective data, Journal:  Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis. (Pubmed Central) -  Jan 27, 2025   
    Further research comparing platelet increases across standardised TPO-RA regimens is recommended to refine treatment strategies. This analysis provides valuable insights for clinicians in tailoring CIT treatment using TPO-RAs.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Journal:  Erenumab in a patient with persistent headaches after subarachnoid hemorrhage: A case report of an effective treatment. (Pubmed Central) -  Jan 27, 2025   
    To our knowledge, this is the first reported case in the literature of a patient with persistent post-subarachnoid hemorrhage headache that was successfully treated with an antibody against the CGRP receptor. This case report highlights the role of CGRP in post-subarachnoid hemorrhage headaches and the potential role for CGRP pathway-based therapies as an effective treatment.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Osteoporosis in Older Men: Informing Patient Management and Improving Health-Related Outcomes. (Pubmed Central) -  Jan 18, 2025   
    Most older men with osteoporosis should be treated with oral or intravenous bisphosphonates, denosumab especially when on androgen deprivation therapy, and initial anabolic treatment should be considered for men at very high risk of fracture. This review summarizes the main features of osteoporosis and fragility fractures in men and reports findings from the available pharmacological and non-pharmacological studies conducted in men.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Clinical, Journal:  Re: Ugradar et (Pubmed Central) -  Jan 17, 2025   
    Compared with SoC, evolocumab No abstract available
  • ||||||||||  Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
    Clinical, Retrospective data, Journal:  First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial. (Pubmed Central) -  Jan 17, 2025   
    P3
    In patients with colorectal cancer and unresectable liver-only metastases (CRLM), treatment with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) plus irinotecan (FOLFOXIRI) and bevacizumab vs FOLFOX/folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus bevacizumab increased progression-free survival, response, and R0/R1 resection/ablation rates, as well as toxic effects in RAS/BRAFV600E-variant and/or right-sided tumors...To present long-term outcomes of treatment with FOLFOXIRI plus bevacizumab vs FOLFOX/FOLFIRI plus bevacizumab and FOLFOX/FOLFIRI plus panitumumab vs FOLFOX/FOLFIRI + bevacizumab...ACT might be considered for these patients. ClinicalTrials.gov NCT02162563.
  • ||||||||||  Jesduvroq (daprodustat) / GSK, Kyowa Kirin
    Journal:  Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial. (Pubmed Central) -  Jan 16, 2025   
    P3
    Zoledronic acid and denosumab use in patients with metastatic bone tumors caused by breast cancer should be done cautiously, considering atypical femoral fracture risk. This subgroup analysis of the ASCEND-D trial demonstrated comparable efficacy and safety of daprodustat versus darbepoetin alfa in PD patients, supporting its use in the treatment of anemia in these patients.
  • ||||||||||  Kepivance (palifermin) / SOBI, Amgen, Rituxan (rituximab) / Roche
    Diagnostic Approaches for Hematopoietic Cell Transplantation Associated Membranous Nephropathy (HCC Exhibit Hall 3; In-Person) -  Jan 15, 2025 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1602;    
    P1/2
    They received a peripheral blood graft from a matched unrelated donor (1/3 female) with tacrolimus/sirolimus/methotrexate GVHD prophylaxis...All patients were treated with rituximab and prednisone for MN...Large, multi-center collaborative studies are needed to identify additional candidate AGs in post-HCT MN that are negative for FAT1 or other common MN AGs. Such studies will better characterize the incidence, risk factors, clinicopathologic features, underlying mechanisms, response to therapy and outcomes in these distinct MN subsets.
  • ||||||||||  Mekinist (trametinib) / Novartis, BeiGene, Vectibix (panitumumab) / Amgen
    Trial completion date, Trial primary completion date:  Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) -  Jan 15, 2025   
    P2,  N=59, Active, not recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026
  • ||||||||||  Ovastat (treosulfan) / Medac, Medexus
    Trial completion date, Trial primary completion date:  Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (clinicaltrials.gov) -  Jan 14, 2025   
    P2,  N=60, Recruiting, 
    Greater baseline disease burden and low albumin were associated with lower sotorasib clearance; based on the established efficacy and safety profiles from clinical trials, the estimated magnitude of these effects does not warrant a dose adjustment. Trial completion date: Dec 2026 --> Jan 2028 | Trial primary completion date: Dec 2024 --> Feb 2026
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Discovery of a novel CDK4/6 and HDAC dual-targeting agent for the treatment of hepatocellular carcinoma. (Pubmed Central) -  Jan 14, 2025   
    Herein, a series of novel CDK4/6 and HDAC dual-targeting inhibitors based on the moiety of palbociclib were designed and synthesized...Furthermore, N14 significantly suppresses the proliferation of various HCC cells and the HuH-7 xenograft model without evident toxicity. Our study suggests compound N14 is a novel dual-targeting CDK4/6-HDAC inhibitor that represents a promising treatment strategy for HCC.
  • ||||||||||  Journal, Surgery, Metastases:  Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma. (Pubmed Central) -  Jan 13, 2025   
    Subsequently, several systemic therapies, including lenvatinib, ramucirumab, cabozantinib, and regorafenib have been investigated and established...Although a combination of atezolizumab and bevacizumab is mostly used for initially unresectable HCC to conduct conversion surgery because of the high response rate and fewer adverse events compared to others, many trials are being conducted to assess their efficacy for initially unresectable HCC...To address these issues, a multidisciplinary team can play a vital role in determining the strategies for treating unresectable HCC. This review describes previous and current trends in the treatment of HCC, with a particular focus on conversion surgery for initially unresectable HCC.
  • ||||||||||  Tavneos (avacopan) / Amgen
    Review, Journal:  Evaluating Avacopan in the Treatment of ANCA-Associated Vasculitis: Design, Development and Positioning of Therapy. (Pubmed Central) -  Jan 13, 2025   
    Combining preclinical studies, clinical trials, and real-world evidence helps to provide a better position of avacopan for the management of AAV in routine clinical practice, taking advantage of the GC-sparing effects of avacopan as a possible solution for the current challenge of reducing GC-toxicity in AAV patients. Furthermore, we delineate current knowledge gaps and future research areas that need to be addressed.
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Biomarker, Journal, Head-to-Head:  Measures of Performance and Clinical Superiority Thresholds for 'Test-and-treat' Predictive Biomarkers. (Pubmed Central) -  Jan 13, 2025   
    More studies are needed on cardiac ablation in this age group and those with structural heart disease in the Middle East region. These intuitive performance measures for predictive biomarkers, based on expected response to individual treatments, can be used to identify promising candidate companion diagnostic tests and indicate the potential magnitude of the net benefit of testing.
  • ||||||||||  Review, Journal:  Emerging oral therapeutic strategies for inhibiting PCSK9. (Pubmed Central) -  Jan 13, 2025   
    Strabismus surgeons may need to weigh the significant risk of disease relapse when planning optimum timing for surgical correction. Subcutaneous administration of monoclonal antibodies (evolocumab and alirocumab) every 2 or 4 weeks determined a 60